Billiontoone (NASDAQ:BLLN) Now Covered by Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Billiontoone (NASDAQ:BLLN) in a report released on Monday morning, MarketBeat Ratings reports. The firm issued an equal weight rating and a $110.00 target price on the stock.

Several other research analysts also recently commented on the stock. Wall Street Zen raised shares of Billiontoone to a “hold” rating in a report on Saturday, November 15th. Piper Sandler assumed coverage on Billiontoone in a research report on Monday. They issued an “overweight” rating and a $150.00 target price on the stock. JPMorgan Chase & Co. started coverage on Billiontoone in a research note on Monday. They set an “overweight” rating and a $150.00 price target for the company. Stifel Nicolaus assumed coverage on Billiontoone in a research note on Monday. They issued a “buy” rating and a $145.00 price objective on the stock. Finally, BTIG Research started coverage on Billiontoone in a report on Monday. They set a “buy” rating and a $160.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Billiontoone currently has an average rating of “Moderate Buy” and a consensus target price of $138.67.

Billiontoone Trading Down 0.1%

BLLN stock traded down $0.07 during trading on Monday, reaching $114.85. The company’s stock had a trading volume of 18,336 shares, compared to its average volume of 193,719. Billiontoone has a 1 year low of $88.00 and a 1 year high of $138.70.

About Billiontoone

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.